These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 621746)

  • 1. Kinetic response to cultured human lymphoid cells to rubidazone.
    Barlogie B; Drewinko B; Benjamin RS
    J Natl Cancer Inst; 1978 Feb; 60(2):279-82. PubMed ID: 621746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of adriamycin on the cell cycle traverse of a human lymphoid cell line.
    Barlogie B; Drewinko B; Johnston DA; Freireich EJ
    Cancer Res; 1976 Jun; 36(6):1975-9. PubMed ID: 1268851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic response of human lymphoid cells to adriamycin-DNA complex in vitro.
    Barlogie B; Drewinko B; Benjamin RS; Freireich EJ
    Cancer Res; 1976 Jul; 36(7 PT 1):2540-4. PubMed ID: 1277154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute cardiovascular alterations induced by low doses of adriamycin, rubidazone, and daunorubicin in the anesthetized beagle dog.
    Herman EH; Young RS
    Cancer Treat Rep; 1979; 63(11-12):1771-9. PubMed ID: 526912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lethality of nogalamycin, nogalamycin analogs, and adriamycin to cells in different cell cycle phases.
    Bhuyan BK; Blowers CL; Shugars KD
    Cancer Res; 1980 Oct; 40(10):3437-42. PubMed ID: 7438031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo.
    Skovsgaard T
    Cancer Chemother Rep; 1975; 59(2 Pt 1):301-8. PubMed ID: 1149008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological activities of rubidazone.
    Maral R
    Cancer Chemother Pharmacol; 1979; 2(1):31-5. PubMed ID: 498417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rubidazone vs adriamycin: an evaluation of their differential toxicity in the spleen colony assay system.
    Alberts DS; Van Daalen Wetters T
    Br J Cancer; 1976 Jul; 34(1):64-8. PubMed ID: 952715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II trial of rubidazone and adriamycin in women with advanced breast cancer.
    Ingle JN; Ahmann DL; O'Fallon JR; Bisel HF; Rubin J; Kvols LK; Giuliani ER
    Cancer Treat Rep; 1979; 63(11-12):1701-5. PubMed ID: 526908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival and cycle-progression delay of cultured human lymphoma cells treated with 1-propanol, 3,3'-iminodi-, dimethanesulfonate (ester), hydrochloride (Yoshi 864).
    Drewinko B; Barlogie B
    Cancer Treat Rep; 1976 Nov; 60(11):1637-45. PubMed ID: 191191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial of rubidazone in solid tumors and malignant lymphomas.
    Skovsgaard T; Hansen HH; Mouridsen HT; Nissen NI; Pedersen-Bjergaard J
    Cancer Treat Rep; 1978 Jul; 62(7):1053-8. PubMed ID: 356967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rubidazone (22 050 RP): clinical study. Phase II trial in solid tumors and lymphomas (author's transl)].
    Chauvergne J; Cappelaere P; Carton M; Gary-Bobo J; Klein T
    Bull Cancer; 1978; 65(1):19-24. PubMed ID: 667371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of adriamycin on the cell cycle traverse and kinetics of cultured human lymphoblasts.
    Krishan A; Frei E
    Cancer Res; 1976 Jan; 36(1):143-50. PubMed ID: 1247994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of new N-alkyl analogues of adriamycin on in vitro survival and cell cycle progression of L1210 cells.
    Traganos F; Israel M; Silber R; Seshadri R; Kirschenbaum S; Potmesil M
    Cancer Res; 1985 Dec; 45(12 Pt 1):6273-9. PubMed ID: 4063977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carrier-mediated transport of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells.
    Skovsgaard T
    Biochem Pharmacol; 1978; 27(8):1221-7. PubMed ID: 567991
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacological and therapeutic efficacy of rubidazone in mice. Comparison with daunomycin and adriamycin.
    Ohnuma T; Elias F; Holland JF; Henderson E
    Eur J Cancer (1965); 1979 Mar; 15(3):363-71. PubMed ID: 446517
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro sensitivity of leukemic clonogenic cells to four anthracyclines (adriamycin, daunorubicin, rubidazone and aclacinomycin) in human acute myeloid leukemia.
    Marie JP; Thevenin D; Zittoun R
    Nouv Rev Fr Hematol (1978); 1985; 27(3):163-7. PubMed ID: 3862071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mode of estrogen action on cell proliferation in CAMA-1 cells: II. Sensitivity of G1 phase population.
    Leung BS; Potter AH
    J Cell Biochem; 1987 Jul; 34(3):213-25. PubMed ID: 3611201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells.
    Ling YH; el-Naggar AK; Priebe W; Perez-Soler R
    Mol Pharmacol; 1996 May; 49(5):832-41. PubMed ID: 8622633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell cycle related uptake, retention and toxicity of idarubicin, daunorubicin and doxorubicin.
    Minderman H; Linssen P; Wessels J; Haanen C
    Anticancer Res; 1993; 13(4):1161-5. PubMed ID: 8352539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.